MAIA Biotechnology (MAIA) Expected to Release Earnings on Monday

MAIA Biotechnology (NYSEAMERICAN:MAIA) is expected to be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.11) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 9:30 AM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. On average, analysts expect MAIA Biotechnology to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

MAIA Biotechnology Stock Performance

Shares of MAIA opened at $1.25 on Monday. The firm has a market capitalization of $75.70 million, a price-to-earnings ratio of -1.87 and a beta of 0.24. The business’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.55. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19.

Insider Transactions at MAIA Biotechnology

In other MAIA Biotechnology news, Director Stan Smith bought 75,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were bought at an average cost of $1.34 per share, for a total transaction of $100,500.00. Following the transaction, the director owned 1,519,178 shares in the company, valued at approximately $2,035,698.52. This trade represents a 5.19% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Vlad Vitoc bought 72,700 shares of MAIA Biotechnology stock in a transaction dated Monday, June 1st. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $101,053.00. Following the purchase, the chief executive officer directly owned 976,121 shares in the company, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 149,700 shares of company stock valued at $204,233. Corporate insiders own 19.81% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently modified their holdings of MAIA. Geode Capital Management LLC raised its position in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Marshall Wace LLP bought a new stake in MAIA Biotechnology in the second quarter valued at approximately $29,000. Finally, Jane Street Group LLC bought a new stake in MAIA Biotechnology in the second quarter valued at approximately $52,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.